Biotechnology company Bristol Myers Squibb (NYSE: BMY) said its first-quarter adjusted earnings increased modestly, despite a decline in revenues. Net income attributable
Bristol-Myers Squibb (BMY) reports higher Q1 profit; revenue down 3%
Categories
Biotechnology
MRK Earnings: Highlights of Merck’s Q1 2023 financial results
Pharma firm Merck & Co., Inc. (NYSE: MRK) on Thursday reported lower earnings for the first quarter of 2023, due to a sharp
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also
Ocean Biomedical reports new results validating tumor suppression with anti-Chi3L1 antibody: EF Hutton raises OCEA price target to $17
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said its scientific co-founder Jack Elias published new findings in Cancer Research, a peer-reviewed
ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for
Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President
BSX Earnings: Highlights of Boston Scientific’s Q1 2023 results
Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the first quarter of 2023. The company also provided guidance for
Illumina Inc (ILMN) Q1 2023 Earnings Call Transcript
Illumina Inc (NASDAQ: ILMN) Q1 2023 earnings call dated Apr. 25, 2023 Corporate Participants: Salli Schwartz -- Vice President of Investor Relations Francis deSouza -- Chief
Ocean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical (OCEA) announces $134 million financial backing for innovative research and IND filings
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Ocean Biomedical gets Notice of Allowance for US patent application for developing new malaria therapeutics
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Bio Path Holdings Inc (BPTH) Q4 2022 Earnings Call Transcript
Bio Path Holdings Inc (NASDAQ: BPTH) Q4 2022 earnings call dated Mar. 31, 2023 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- Chief Executive
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic
Walgreens Boots Alliance (WBA) shifts to expansion mode. Will it pay off?
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in retail pharmacy, has regularly revised its business model to better align with
Ocean Biomedical presents novel malaria therapeutic discoveries at NIH Laboratory of Malaria Vaccinology and Immunology
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Fundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday said that Fundamental Research Corp. initiated equity analyst coverage of its stock with a “Buy”
Ocean Biomedical provides positive research data on anti-tumor pathway; stock climbs
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) released details of discoveries that have potential applications for tumor suppression across multiple cancer pathways.
Novavax Inc (NVAX) Q4 2022 Earnings Call Transcript
Novavax Inc (NASDAQ:NVAX) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Erika Schultz -- Senior Director of Investor Relations John Jacobs -- President and
Ocean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jonathan Kurtis received a new patent for his discovery related
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
The global pharmaceutical market is expected to cross $1.5 trillion this year, which represents a 4-5% annual growth over the past five